<DOC>
	<DOC>NCT01224730</DOC>
	<brief_summary>This is a Phase I study which will analyze any food-drug effects as well as QTc effects of perifosine. Safety and efficacy will also be evaluated. Patients who complete the first 24 days on single agent perifosine may have the opportunity to 1) continue on single agent perifosine; 2) switch to the combination of capecitabine + perifosine; or 3) switch to the combination of sorafenib + perifosine.</brief_summary>
	<brief_title>A Food Effect and QTc Study of Perifosine in Patients With Advanced Malignancies</brief_title>
	<detailed_description />
	<criteria>Patients with advanced malignancies Patients with adequate organ and marrow function Patients previously treated with perifosine Patients receiving any other chemotherapy, targeted agents, investigational agents or devices within four weeks (28 days) prior to Day 1 of study treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
</DOC>